The GLP-1 revolution is here — and aesthetics clinics must adapt
The global rise of GLP-1 weight-loss medications is reshaping how people think about weight, wellness, and appearance. According to industry analysis, GLP-1 prescriptions have grown around 38% annually between 2022 and 2024, driven by expanded indications and broader adoption in obesity care.
In Great Britain (England, Wales and Scotland), an estimated 1.6 million adults had used GLP-1 drugs to support weight loss between early 2024 and early 2025. Meanwhile, about 3.3 million adults in the UK reported they would be interested in trying weight-loss medications in 2026.
These trends reflect a massive shift in public behaviour and perception around weight loss — and a corresponding shift in aesthetic concerns.
New patient demographics emerge for aesthetic practices
Clinics are increasingly encountering patients whose first interaction with medical aesthetics comes after significant GLP-1-induced weight loss. According to industry surveys (your supplied data), after GLP-1 treatments:
-
63 % of patients seeking facial aesthetic procedures were new to medical aesthetics (industry survey).
-
82 % of patients wanted to address skin laxity following GLP-1 treatments (industry survey).
These figures align with broader clinical observations that rapid weight loss often leads to volume loss and skin laxity, particularly in areas like the face, neck and body.
“Ozempic Face”, “Ozempic Butt” & the mainstream makeover conversation
Even mainstream media has picked up terms such as “Ozempic face” to describe facial thinning and sagging associated with rapid weight loss.
Clinically, rapid weight loss reduces underlying fat that supports skin structure, which can result in:
-
sunken cheeks and hollowed temples
-
deeper nasolabial folds
-
sagging jowls and overall skin laxity
These effects are seen both in surgical and nonsurgical contexts — and they’re exactly the sorts of concerns patients now bring to aesthetic clinics.
Why this demand is an opportunity — not a threat
The exponential interest in GLP-1 medications presents a huge commercial opportunity for aesthetic clinics willing to adapt their service offerings:
1. Address facial volume loss with HA fillers
Hyaluronic acid fillers (e.g., Revanesse) are ideal for restoring lost volume and countering aging effects caused by rapid fat reduction.
2. Treat skin laxity with advanced devices
Body-refinement platforms (such as Alma PrimeX) offer non-invasive tightening and contouring — especially for areas like the abdomen, arms and thighs where laxity is often most noticeable post-weight loss.
Clinics that embrace these solutions — and market them as part of a dedicated GLP-1 aftercare pathway — position themselves as leaders in a rapidly evolving industry.
Dr. Fernando Urdiales, Dr. Ines Verner, Dr. Ko Jung 
